News

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® ...
Everyday Health on MSN1h
FDA Approves a ‘Game-Changing’ Twice-a-Year HIV Prevention Shot
The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or every-other-month injections.
Public Broadcasting Service (PBS)40m
6 things to know about lenacapavir, what experts call a ‘wonder drug’ for preventing HIV
The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...
HealthDay on MSN1h
FDA Approves Twice-Yearly Yeztugo for Preexposure Prophylaxis to Cut HIV Risk
The U.S. Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as ...
MPR6h
Twice-Yearly HIV-1 PrEP Yeztugo Gets FDA Approval
Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.
India Today on MSN1d
Lenacapavir becomes first FDA-approved HIV preventive drug: All about it
The US FDA has approved lenacapvir, sold under the brand name Yeztugo, as the first preventive treatment against HIV. It is a ...
HIV prevention drug lenacapavir approved by FDA as twice-yearly injection
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...
Pharmabiz18h
Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection
Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection: Foster City, California Friday, June 20, 2025, 1 ...
GlobalData on MSN1d
Gilead Sciences’ Yeztugo receives approval from US FDA for HIV
The US Food and Drug Administration (FDA) has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a ...
BioSpace1d
Gilead Wins Historic Approval for Twice-Yearly HIV Drug
“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in the company’s announcement.
Managed Healthcare Executive2d
FDA Approves Lenacapavir as the First Twice-Yearly PrEP for HIV Prevention
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
STAT2d
HIV protection with just two shots a year: FDA approves Gilead drug
A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...